Short Interest in Sera Prognostics, Inc. (NASDAQ:SERA) Decreases By 19.6%

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) was the target of a significant drop in short interest in January. As of January 15th, there was short interest totalling 844,400 shares, a drop of 19.6% from the December 31st total of 1,050,000 shares. Based on an average daily volume of 102,700 shares, the short-interest ratio is presently 8.2 days. Currently, 4.0% of the shares of the stock are sold short.

Sera Prognostics Price Performance

Shares of Sera Prognostics stock traded up $0.08 on Wednesday, reaching $5.04. 128,874 shares of the company were exchanged, compared to its average volume of 107,164. The stock's 50 day moving average price is $7.31 and its 200-day moving average price is $7.31. The company has a market cap of $170.20 million, a P/E ratio of -5.09 and a beta of 0.81. Sera Prognostics has a 1-year low of $4.61 and a 1-year high of $12.35.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.09 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share. On average, research analysts predict that Sera Prognostics will post -0.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Sera Prognostics

In other Sera Prognostics news, General Counsel Benjamin Jackson sold 4,727 shares of Sera Prognostics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $7.32, for a total value of $34,601.64. Following the completion of the transaction, the general counsel now directly owns 135,528 shares of the company's stock, valued at $992,064.96. The trade was a 3.37 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Paul Kearney sold 4,078 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $29,850.96. Following the completion of the transaction, the insider now directly owns 176,889 shares of the company's stock, valued at approximately $1,294,827.48. The trade was a 2.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 93,215 shares of company stock valued at $666,835 over the last ninety days. Corporate insiders own 15.80% of the company's stock.

Hedge Funds Weigh In On Sera Prognostics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its holdings in shares of Sera Prognostics by 7,357.8% in the third quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company's stock valued at $6,902,000 after purchasing an additional 873,002 shares during the period. Geode Capital Management LLC increased its stake in Sera Prognostics by 8.9% in the 3rd quarter. Geode Capital Management LLC now owns 586,837 shares of the company's stock valued at $4,578,000 after buying an additional 47,969 shares during the period. State Street Corp raised its position in Sera Prognostics by 8.8% during the 3rd quarter. State Street Corp now owns 425,093 shares of the company's stock worth $3,316,000 after buying an additional 34,479 shares during the last quarter. Sanders Morris Harris LLC lifted its stake in shares of Sera Prognostics by 165.7% in the 4th quarter. Sanders Morris Harris LLC now owns 90,600 shares of the company's stock worth $725,000 after acquiring an additional 56,500 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Sera Prognostics by 321.6% in the third quarter. Barclays PLC now owns 39,450 shares of the company's stock valued at $308,000 after acquiring an additional 30,093 shares in the last quarter. Hedge funds and other institutional investors own 54.64% of the company's stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.